-

Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present (live) at the William Blair 42nd Annual Growth Stock Conference on Monday, June 6, 2022 at 2:00pm CT.

ABOUT ABIOMED

Based in Danvers, Massachusetts, USA, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts

Investor:
Todd Trapp
Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com

Media:
Jenny Leary
Associate Director, U.S. Communications
+1 (978) 882-8491
jleary@abiomed.com

Industry:

Abiomed, Inc.

NASDAQ:ABMD
Release Summary
Abiomed to present (live) at the William Blair 42nd Annual Growth Stock Conference.
Release Versions
English

Contacts

Investor:
Todd Trapp
Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com

Media:
Jenny Leary
Associate Director, U.S. Communications
+1 (978) 882-8491
jleary@abiomed.com

More News From Abiomed, Inc.

FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed Announces First Patients Enrolled in FDA Pivotal Trial for Impella ECP, World’s Smallest Heart Pump...

First Patients in the World Treated with Impella RP Flex with SmartAssist

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist....

Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed today announces financial results for the quarter ended September 30, 2022....
Back to Newsroom